Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eos… (NCT07602881) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With Biologics
China500 participantsStarted 2026-06-01
Plain-language summary
Firstly, to screen blood exosomal multi-omics (transcriptomics, proteomics, metabolomics) and lung radiomics (HRCT, Xe129MRI) biomarkers that can predict efficacy and prognosis in severe eosinophilic ACOS (asthma-COPD overlap) patients treated with different biologics (benralizumab, mepolizumab, dupilumab). Then, to prospectively follow patients for 48 weeks after biologic initiation and collect clinical data, blood samples, and imaging features. Finally, to build a multi-dimensional predictive model for efficacy and prognosis of severe eosinophilic ACOS.
Who can participate
Age range
14 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 14 years
* Clinician decision to start biologic (benralizumab, mepolizumab, or dupilumab) for severe eosinophilic ACOS
* Blood eosinophils ≥150/μL within 3 months prior to informed consent, or ≥300/μL within 1 year prior
* Signed written informed consent
Exclusion Criteria:
* Currently participating in any other interventional clinical trial
* Known allergy or hypersensitivity to any component of the study drugs
* Any type of malignancy
* Prior or current biologic treatment for ACOS
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial is focused on severe eosinophilic ACOS — a combination of both asthma and COPD with high eosinophil levels — can you help me understand whether my diagnosis fits that specific profile, and why that distinction matters for whether biologics might be considered for me?
2This study is measuring blood biomarkers and lung imaging to predict how well biologics work over 48 weeks — does that mean participants are already receiving biologic therapy, and if so, is that a treatment path you'd consider for me regardless of whether I join a study like this?
3The trial isn't recruiting yet — given that timeline uncertainty, should I be pursuing a different treatment plan now rather than waiting to see if this study opens and I might be eligible?
4This appears to be an observational or predictive study rather than a trial testing a new treatment — can you explain what that means for me practically, including what procedures like blood draws or lung imaging would actually involve if I were to participate?
5Since the trial is tracking outcomes all the way to 48 weeks, what would my standard-of-care options look like over that same timeframe, and how would joining a study like this compare to just following a regular treatment plan with you?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Composite efficacy and prognosis endpoint at week 48 in severe eosinophilic ACOS
Timeframe: 48 weeks after the first dose of biologic
Trial details
NCT IDNCT07602881
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology